Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials.
Megan MoscaJulie HongEdward HadelerMarwa HakimiNicholas BrownstoneWilson LiaoTina BhutaniPublished in: Dermatology and therapy (2021)
The association between psoriasis, metabolic syndrome, and cardiovascular disease is well established. The shared pathways between psoriasis, metabolic syndrome, and atherosclerosis suggest that treatments targeting the inflammatory pathways of psoriasis may also be beneficial in the treatment of associated cardiometabolic comorbidities. This paper reviews the most recent data regarding the impact of systemic psoriasis treatments on comorbid cardiovascular and metabolic disease. Data from randomized clinical trials with systemic and biologic agents are presented. Overall, studies demonstrate beneficial effects on several cardiometabolic markers and risk factors in psoriasis patients; however, longer randomized controlled trials to characterize the direct benefit for cardiovascular outcomes are needed.
Keyphrases
- metabolic syndrome
- cardiovascular disease
- risk factors
- end stage renal disease
- atopic dermatitis
- randomized controlled trial
- rheumatoid arthritis
- chronic kidney disease
- ejection fraction
- type diabetes
- big data
- uric acid
- oxidative stress
- coronary artery disease
- skeletal muscle
- cardiovascular risk factors
- peritoneal dialysis
- clinical trial
- drug delivery
- patient reported outcomes
- cancer therapy
- cardiovascular events
- deep learning